BridgeBio Pharma will announce its Q2 2026 financial results on August 10, 2026, followed by a conference call.
Quiver AI Summary
BridgeBio Pharma, Inc. announced it will release its second quarter 2026 financial results and business update on August 10, 2026, after the market closes. A conference call to discuss these results and program updates will be held at 4:30 pm ET that same day, with a live webcast available on the company's website. A replay will be accessible for 30 days post-event. BridgeBio focuses on developing medicines for genetic conditions, aiming to provide treatments for underserved populations through a unique operational model that promotes efficiency and innovation. Further information can be found on their website and social media platforms.
Potential Positives
- BridgeBio Pharma scheduled a conference call for August 10, 2026, to discuss its second quarter financial results and program updates, indicating transparency and engagement with investors.
- The company's focus on developing medicines for genetic conditions highlights its commitment to addressing unmet medical needs, which can enhance its reputation and attract potential partnerships.
- BridgeBio’s innovative hub-and-spoke model aims for speed, precision, and scalability, showcasing its strategic approach to drug development that could lead to successful product launches.
Potential Negatives
- Announcement of financial results and business update does not indicate any positive developments or progress, which may raise concerns among investors about the company's current performance.
- The focus on developing medicines for genetic conditions implies ongoing challenges in addressing the needs of small patient populations, potentially indicating commercial risks.
- While the company promotes its decentralized model, there's no mention of recent successes or advancements, which could lead to skepticism about its effectiveness and future prospects.
FAQ
When will BridgeBio release its second quarter financial results?
BridgeBio will release its second quarter 2026 financial results on August 10, 2026, after market close.
How can I access the BridgeBio conference call?
You can access the conference call on August 10, 2026, at 4:30 pm ET via the webcast link on the BridgeBio website.
Will there be a replay of the conference call available?
Yes, a replay of the conference call will be available on the BridgeBio website for 30 days following the event.
What is BridgeBio's mission?
BridgeBio's mission is to develop transformative medicines for genetic conditions, addressing the needs of underserved patient populations.
How can I contact BridgeBio for media inquiries?
For media inquiries, contact Bubba Murarka at contact@bridgebio.com or call (650)-789-8220.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Quiver Alerts
Receive BBIO Data Alerts
Get market-moving data, filings, and signals for BBIO in real time.
Sign Up
$BBIO Insider Trading Activity
$BBIO insiders have traded $BBIO stock on the open market 74 times in the past 6 months. Of those trades, 0 have been purchases and 74 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 52 sales selling 374,156 shares for an estimated $26,447,042.
- JENNIFER E. COOK has made 0 purchases and 6 sales selling 278,192 shares for an estimated $21,920,434.
- ANDREA ELLIS has made 0 purchases and 2 sales selling 82,088 shares for an estimated $5,653,329.
- RANDAL W. SCOTT has made 0 purchases and 7 sales selling 20,000 shares for an estimated $1,426,012.
- THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 2 sales selling 13,600 shares for an estimated $1,016,147.
- HANNAH VALANTINE has made 0 purchases and 3 sales selling 13,675 shares for an estimated $965,835.
- MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,510 shares for an estimated $181,058.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BBIO Congressional Stock Trading
Members of Congress have traded $BBIO stock 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
$BBIO Hedge Fund Activity
We have seen 233 institutional investors add shares of $BBIO stock to their portfolio, and 191 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BROOKLANDS FUND MANAGEMENT LTD removed 2,750,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $204,215,000
- VIKING GLOBAL INVESTORS LP removed 2,551,500 shares (-17.7%) from their portfolio in Q1 2026, for an estimated $189,474,390
- CITADEL ADVISORS LLC added 2,475,758 shares (+354.6%) to their portfolio in Q1 2026, for an estimated $183,849,789
- JANE STREET GROUP, LLC added 1,415,877 shares (+414.2%) to their portfolio in Q1 2026, for an estimated $105,143,026
- POLAR CAPITAL HOLDINGS PLC added 1,219,960 shares (+93.9%) to their portfolio in Q1 2026, for an estimated $90,594,229
- TWO SIGMA INVESTMENTS, LP added 1,173,584 shares (+60.3%) to their portfolio in Q1 2026, for an estimated $87,150,347
- CAPITAL RESEARCH GLOBAL INVESTORS removed 1,170,996 shares (-60.5%) from their portfolio in Q1 2026, for an estimated $86,958,162
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BBIO Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 03/10/2026
To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.
$BBIO Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 11 analysts offer price targets for $BBIO in the last 6 months, with a median target of $98.0.
Here are some recent targets:
- Salim Syed from Mizuho set a target price of $96.0 on 06/16/2026
- Whitney Ijem from Canaccord Genuity set a target price of $104.0 on 06/03/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $110.0 on 05/28/2026
- Sean Laaman from Morgan Stanley set a target price of $98.0 on 05/28/2026
- Eric Joseph from Citigroup set a target price of $82.0 on 05/19/2026
- Cory Kasimov from Evercore ISI Group set a target price of $130.0 on 05/08/2026
- Danielle Brill from Truist Securities set a target price of $102.0 on 04/29/2026
Full Release
PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its second quarter 2026 financial results and business update after the market closes on Monday, August 10, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.
To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at
investor.bridgebio.com/events-and-presentations/
. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
Participants may access the webcast by registering online using the following link,
here.
About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit
bridgebio.com
and follow us on
LinkedIn
,
X
,
Facebook
,
Instagram
,
YouTube
, and
TikTok
.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com
Read full article here »
View the Zacks #1 Rank List
BridgeBio Pharma Announces Date for Second Quarter 2026 Financial Results and Business Update
BridgeBio Pharma will announce its Q2 2026 financial results on August 10, 2026, followed by a conference call.
Quiver AI Summary
BridgeBio Pharma, Inc. announced it will release its second quarter 2026 financial results and business update on August 10, 2026, after the market closes. A conference call to discuss these results and program updates will be held at 4:30 pm ET that same day, with a live webcast available on the company's website. A replay will be accessible for 30 days post-event. BridgeBio focuses on developing medicines for genetic conditions, aiming to provide treatments for underserved populations through a unique operational model that promotes efficiency and innovation. Further information can be found on their website and social media platforms.
Potential Positives
Potential Negatives
FAQ
When will BridgeBio release its second quarter financial results?
BridgeBio will release its second quarter 2026 financial results on August 10, 2026, after market close.
How can I access the BridgeBio conference call?
You can access the conference call on August 10, 2026, at 4:30 pm ET via the webcast link on the BridgeBio website.
Will there be a replay of the conference call available?
Yes, a replay of the conference call will be available on the BridgeBio website for 30 days following the event.
What is BridgeBio's mission?
BridgeBio's mission is to develop transformative medicines for genetic conditions, addressing the needs of underserved patient populations.
How can I contact BridgeBio for media inquiries?
For media inquiries, contact Bubba Murarka at contact@bridgebio.com or call (650)-789-8220.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BBIO Insider Trading Activity
$BBIO insiders have traded $BBIO stock on the open market 74 times in the past 6 months. Of those trades, 0 have been purchases and 74 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BBIO Congressional Stock Trading
Members of Congress have traded $BBIO stock 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
$BBIO Hedge Fund Activity
We have seen 233 institutional investors add shares of $BBIO stock to their portfolio, and 191 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BBIO Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.
$BBIO Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 11 analysts offer price targets for $BBIO in the last 6 months, with a median target of $98.0.
Here are some recent targets:
Full Release
PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its second quarter 2026 financial results and business update after the market closes on Monday, August 10, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.
To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/ . A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
Participants may access the webcast by registering online using the following link, here.
About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn , X , Facebook , Instagram , YouTube , and TikTok .
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com
Read full article here »